phospholipase D family member 3Genealiases: AD19 · HU-K4 · HUK4 · SCA46
Q-omics provides the consensus-scored PLD3 profile across patient tissues and cancer cell-line models. PLD3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PLD3 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PLD3 RNA expression shows 18,083 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where PLD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLD3 survival associations across molecular data types. PLD3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLD3 RNA expression–survival associations across cancer types. High PLD3 expression shows unfavorable associations in LGG, BLCA and ACC, but favorable associations in KIRC, LUAD and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for PLD3 RNA expression.
This table summarizes PLD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PLD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLD3 shows higher tumor expression in HNSC, KIRC, KIRP, THCA, LIHC and STAD. The HNSC box plot shows higher PLD3 RNA expression in tumor versus normal tissue (log2 FC = +1.086, t-test p < 0.001).
This table shows molecular features associated with PLD3 in patient tissues and cancer cell lines. In patient samples, PLD3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
